Evidence map›Paper›PMID 33714260›Full record

ArticleBosnian journal of basic medical sciences2021

The impact of Ki-67 index, squamous differentiation, and several clinicopathologic parameters on the recurrence of low and intermediate-risk endometrial cancer.

Birol Ocak, Fatma Öz Atalay, Ahmet Bilgehan Sahin, Mine Ozsen, Bahar Dakiki, Seray Türe, Merve Mesohorli, Hikmet Utku Odman, Özgür Tanrıverdi, Gökhan Ocakoğlu and 8 more

Abstract read
In one paragraph

Article in Bosnian journal of basic medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Birol OcakDepartment of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey.
Fatma Öz AtalayDepartment of Surgical Pathology, Faculty of Medicine, Uludag University, Bursa, Turkey.
Ahmet Bilgehan SahinDepartment of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey.
Mine OzsenDepartment of Surgical Pathology, Faculty of Medicine, Uludag University, Bursa, Turkey.
Bahar DakikiDepartment of Internal Medicine, Faculty of Medicine, Uludag University, Bursa, Turkey.
Seray TüreDepartment of Internal Medicine, Faculty of Medicine, Uludag University, Bursa, Turkey.
Merve MesohorliDepartment of Internal Medicine, Faculty of Medicine, Uludag University, Bursa, Turkey.
Hikmet Utku OdmanDepartment of Internal Medicine, Faculty of Medicine, Uludag University, Bursa, Turkey.
Özgür TanrıverdiDepartment of Medical Oncology, Faculty of Medicine, Sitki Kocman University, Mugla, Turkey.
Gökhan OcakoğluDepartment of Biostatistics, Faculty of Medicine, Uludag University, Bursa, Turkey.
Mehmet BayrakDepartment of Gynecologic Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey.
Hakan OzanDepartment of Gynecologic Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey.
Candan DemirözDepartment of Radiation Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey.
Seda SaliDepartment of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey.
Sibel Oyucu OrhanDepartment of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey.
Adem DeligönülDepartment of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey.
Erdem CubukcuDepartment of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey.
Türkkan EvrenselDepartment of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial endometrioid carcinoma (EEC) represents approximately 75-80% of endometrial carcinoma cases. Three hundred and thirty-six patients with EEC followed-up in the authors' medical center between 2010 and 2018 were included in our study. Two hundred and seventy-two low and intermediate EEC patients were identified using the European Society for Medical Oncology criteria and confirmed by histopathological examination. Recurrence was reported in 17 of these patients. The study group consisted of patients with relapse. A control group of 51 patients was formed at a ratio of 3:1 according to age, stage, and grade, similar to that in the study group. Of the 17 patients with recurrent disease, 13 patients (76.5%) were Stage 1A, and 4 patients (23.5%) were Stage 1B. No significant difference was found in age, stage, and grade between the case and control groups (p > 0.05). Body mass index, parity, tumor size, lower uterine segment involvement, SqD, and Ki-67 index with p<0.25 in the univariate logistic regression analysis were included in the multivariate analysis. Ki-67 was statistically significant in multivariate analysis (p = 0.018); however, there was no statistical significance in SqD and other parameters. Our data suggest that the Ki-67 index rather than SqD needs to be assessed for recurrence in patients with low- and intermediate-risk EEC.

Indexed as

AdultAgedBiomarkers, TumorCarcinoma, Squamous CellCase-Control StudiesEndometrial NeoplasmsFemaleHumansKi-67 AntigenMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingRetrospective StudiesRisk FactorsBiomarkers, TumorKi-67 Antigen

Identifiers

PMID33714260
PMCPMC8381206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.